Primary Care Products

Discussion in 'Astellas' started by anonymous, Aug 9, 2018 at 3:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Currently, what are the products the primary care sales force is selling? Any new ones on the horizon? (I have an interview and I wanted to do some research.) Thanks in advance!
     

  2. anonymous

    anonymous Guest

    Ask Google.
     
  3. anonymous

    anonymous Guest

    Urology pills. One you get paid on one is counted against you.
    Bright and shiny horizons at Astellas.
    Ask in the interview why 7-8 upper managers left including the president of the Americas in the last 8 months.
    Ask why this position is open.
     
  4. anonymous

    anonymous Guest

    sinkng ship. Stay far away.
     
  5. anonymous

    anonymous Guest

    Myrbetriq and Vesicare. Overactive bladder drugs. Myrbetriq relaxes the bladder and allows for more storage which sets it apart from antimuscarinics/other OAB drugs.

    Technically we are now indicated for combo therapy between the two but realistically we pretend vesicare doesn’t exist because it’s our competition now...yeah don’t ask.

    Good luck in your interview.
     
  6. anonymous

    anonymous Guest

    Vesicare is going generic in 2018.
    Myrbetriq is the only PC drug.
    The company is going under, unless it buys something big (like Takeda did with Shire) or is bought out. Xtandi is the only blockbuster drug it has, and it is shared with Pfizer. Maybe Pfizer will bolt-on Astellas and erase it from the map?
     
  7. anonymous

    anonymous Guest

    Vesicare is going generic in mid-2019 at the earliest. Myrbetriq will go generic in late-2022, or even later pending some court decisions. The big wildcard for the Primary Care sales force is fezolinetant (post-menopausal hot flashes), which would be prescribed by both PCPs and ObGyns. It could be huge (i.e., bigger than Xtandi). Stay tuned...
     
  8. anonymous

    anonymous Guest

    Well said